Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection.
Castro-Balado A, Mondelo-García C, Barbosa-Pereira L, Varela-Rey I, Novo-Veleiro I, Vázquez-Agra N, Antúnez-López JR, Bandín-Vilar EJ, Sendón-García R, Busto-Iglesias M, Rodríguez-Bernaldo de Quirós A, García-Quintanilla L, González-Barcia M, Zarra-Ferro I, Otero-Espinar FJ, Rey-Bretal D, Lago-Quinteiro JR, Valdés-Cuadrado L, Rábade-Castedo C, Del Río-Garma MC, Crespo-Diz C, Delgado-Sánchez O, Aguiar P, Barbeito-Castiñeiras G, Pérez Del Molino-Bernal ML, Trastoy-Pena R, Passannante R, Llop J, Pose-Reino A, Fernández-Ferreiro A.
Castro-Balado A, et al. Among authors: perez del molino bernal ml.
Pharmaceutics. 2021 Mar 5;13(3):342. doi: 10.3390/pharmaceutics13030342.
Pharmaceutics. 2021.
PMID: 33808025
Free PMC article.